ArticleNature2020
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
5 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,293 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,293citing papers in PubMed, 3 pooled it
48.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against SARS-CoV-2 Virus Infection
Methodological Design for Evaluating the Immune Capacity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Human Infection: Intelligent Medicine Integration.
Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
NCT05710783 phase2 / phase3completednot on this mapstarted 2022, after this paper: background citation
Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2
Who cites it
1,293 citing papers in PubMed, 3 syntheses or guidelines pooled it, 2,143 citations in OpenAlex.
- Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis.Immunologic research · 2024Pooled it
- Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.BMC infectious diseases · 2025Trial
- No clear evidence of PFAS-induced immunomodulation in SARS-CoV-2-specific human T cell responses following vaccination.Archives of toxicology · 2026Article
- The challenge and promise of studying human antigen-specific T cells.Nature reviews. Immunology · 2026Review
- A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations.Molecular therapy. Advances · 2026Article
- Early Immunological Biomarkers for Personalized Treatment Selection in Severe COVID-19: Post Hoc Machine Learning Analysis of a Randomized Clinical Trial.JMIR medical informatics · 2026Article
- Comprehensive longitudinal profiling identifies differential frequency, epitope specificity, and effector function of CD8EBioMedicine · 2026Article
- SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine.Applied microbiology and biotechnology · 2026Article
- Whole-protein screening and multi-modal profiling of antigen-specific CD4Nature communications · 2026Article
- Mechanisms underlying immunodynamics of layered defenses elicited by mRNA vaccination in children.BMC medicine · 2026Article
- Immunological memory to vaccines.Immunity · 2026Review
- Serial vaccination expands and refines human CD4bioRxiv : the preprint server for biology · 2026Article
- Design and immunogenicity evaluation of pan-recombinant vaccines based on the consensus sequence of severe acute respiratory syndrome coronavirus-2 spike protein.Scientific reports · 2026Article
- Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses.Nature communications · 2026Article
- Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host.iScience · 2026Article
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- De novo identification of the specificities of recurrently identified human T cell receptors.Science advances · 2026Article
1,233 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 1 country.
Nina Le Bert *Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Anthony T Tan *Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Kamini KunasegaranEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Christine Y L ThamEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Morteza HafeziEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Adeline ChiaEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Melissa Hui Yen ChngEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Meiyin LinEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Nicole TanEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Martin LinsterEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Wan Ni ChiaEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.
Mark I-Cheng ChenNational Centre of Infectious Diseases, Singapore, Singapore.
Lin-Fa WangEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.ORCID http://orcid.org/0000-0003-2752-0535
Eng Eong OoiEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.ORCID http://orcid.org/0000-0002-0520-1544
Shirin KalimuddinDepartment of Infectious Diseases, Singapore General Hospital, Singapore, Singapore.
Paul Anantharajah TambyahDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Jenny Guek-Hong LowEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore.ORCID http://orcid.org/0000-0002-3876-2209
Yee-Joo TanInstitute of Molecular and Cell Biology (IMCB), A*STAR, Singapore, Singapore.
Antonio BertolettiEmerging Infectious Diseases Program, Duke-NUS Medical School, Singapore, Singapore. antonio@duke-nus.edu.sg.ORCID http://orcid.org/0000-0002-2942-0485
Duke-NUS Medical School · SGAgency for Science, Technology and Research · SGSingapore General Hospital · SGNational Centre for Infectious Diseases · SGNational University of Singapore · SG
Funding
No grant is acknowledged in the PubMed record.
Abstract
Memory T cells induced by previous pathogens can shape susceptibility to, and the clinical severity of, subsequent infections
Indexed as
BetacoronavirusCase-Control StudiesCoronavirus InfectionsCoronavirus Nucleocapsid ProteinsCOVID-19Cross ReactionsHumansImmunodominant EpitopesNucleocapsid ProteinsPandemicsPhosphoproteinsPneumonia, ViralSARS-CoV-2Severe Acute Respiratory SyndromeT-LymphocytesCoronavirus Nucleocapsid ProteinsImmunodominant Epitopesnucleocapsid phosphoprotein, SARS-CoV-2Nucleocapsid ProteinsPhosphoproteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04854876ClinicalTrials.gov
NCT05054075ClinicalTrials.gov
NCT05205746ClinicalTrials.gov
NCT05568953ClinicalTrials.gov
NCT05710783ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.